YB1 and why triple-negative breast cancer affects Black women more severely
Role of YB1 in health disparities in triple negative breast cancer
['FUNDING_R01'] · CASE WESTERN RESERVE UNIVERSITY · NIH-11323909
This project looks at whether higher YB1 activity in tumors helps explain why triple-negative breast cancer is more aggressive and less responsive to chemotherapy in African American women.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CASE WESTERN RESERVE UNIVERSITY (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-11323909 on ClinicalTrials.gov |
What this research studies
From a patient's point of view, researchers will compare tumor samples from African American and Caucasian women with triple-negative breast cancer to measure YB1 levels, location in the cell, and a specific activating mark (phosphorylation). They will link those measurements to clinical outcomes like recurrence and survival and to features of cancer stem cells and chemotherapy resistance. Laboratory experiments will change YB1 activity in cancer cells and animal models to see how that alters invasion, metastasis, and drug response. The goal is to reveal biological differences that may explain outcome disparities and point to possible new targets for treatment.
Who could benefit from this research
Good fit: People with triple-negative breast cancer—especially African American/Black women—or patients willing to provide tumor tissue or clinical data would be most relevant to this work.
Not a fit: Patients without triple-negative breast cancer or those who cannot provide tumor samples are unlikely to directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could identify YB1-driven mechanisms to target, potentially reducing recurrence and improving survival for Black women with triple-negative breast cancer.
How similar studies have performed: Prior laboratory and tumor-profile studies have linked YB1 to aggressive tumor behavior and chemotherapy resistance, but translating those findings into proven therapies is still largely untested.
Where this research is happening
CLEVELAND, UNITED STATES
- CASE WESTERN RESERVE UNIVERSITY — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SOSSEY-ALAOUI, KHALID — CASE WESTERN RESERVE UNIVERSITY
- Study coordinator: SOSSEY-ALAOUI, KHALID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Breast Cancer Patient